Clinical trials: Obesity & Overweight
Haemophilia A, Haemophilia B, Obesity
Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)
An online web-based cross-sectional survey in which participants will complete a distinct questionnaire for patients with hemophilia and obesity (PwHO) and/or their carers/spouses/partners, or a distinct questionnaire for…
- Trial name
- ACTION to HOPE (NCT03430154)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Novo Nordisk A/S
Obesity
Mind/Body Stress Management to Improve Outcomes in Workplace Weight Loss Programs
The purpose of this study is to explore the efficacy of a phone-based weight loss program that has stress management techniques integrated throughout (Weight Talk-Mindfulness).
- Trial name
- NCT02198196
- Testing
- Weight Talk-Mindfulness
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Consumer Wellness Solutions
Healthy, Obese
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese…
- Conditions
- Healthy, Obese, Overweight, Obesity
- Trial name
- NCT06440980
- Testing
- Orforglipron
- Where
- 7 sites in United States
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus
- Trial name
- NCT06174779
- Testing
- HM11260C
- Where
- South Korea
- Volunteers
- 448 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity & Overweight
A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.
The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.
- Trial name
- NCT07890870
- Testing
- IBIO-610
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with…
- Trial name
- BMT-801 (NCT06565611)
- Testing
- bremelanotide, tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Palatin Technologies, Inc
Obesity, Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Weight Maintenance
- Trial name
- NCT07553299
- Testing
- VRB-101
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Verdiva Bio Dev Limited
Obesity, Overweight
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
The purpose of this Phase 3b study is to assess the effects of combination therapy with naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle intervention (CLI) and in a manner consistent with its…
- Trial name
- NCT01764386
- Testing
- NB, CLI, Usual Care
- Where
- 15 sites in United States
- Volunteers
- 242 people
- Sponsor
- Orexigen Therapeutics, Inc
Overweight, Obesity
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in…
- Conditions
- Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
- Trial name
- SOLIS-1 (NCT07575932)
- Testing
- PF-08653945, PF-08653944
- Where
- 63 sites in United States, Canada
- Volunteers
- 940 people
- Sponsor
- Pfizer
Obesity
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
- Trial name
- NCT03757130
- Testing
- AMG 598, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus Combined With Overweight or Obesity
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study designed to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of multiple oral doses of TQF3250…
- Trial name
- NCT07747857
- Testing
- TQF3250 capsules
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Healthy Volunteers
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.
- Trial name
- NCT06139055
- Testing
- GSBR-1290 (Capsule/Tablet), GSBR-1290
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
SUCCESS Tracking Study
The overall purpose of this research is to evaluate the long-term outcomes associated with participation in Medifast Direct and Take Shape For Life weight-loss programs in comparison with non-Medifast weight-loss programs.
- Trial name
- NCT01021917
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Medifast, Inc.
Obesity, Morbid Obesity
Abiliti™ Treatment in Obese Subjects
The main objective of this post-market surveillance study is to compare the subject's weight loss and quality of life, and device safety performance of the abiliti System and the adjustable gastric banding therapies in obese to…
- Trial name
- NCT01448785
- Testing
- abiliti system implant, Laparoscopic adjustable gastric band (Allergan Lap Band)
- Where
- 15 sites in France, Germany and 4 more
- Volunteers
- 165 people
- Sponsor
- IntraPace, Inc
Type 2 Diabetes Mellitus
A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes
It is a phase II, randomized, double-blind, placebo-controlled study of P2202 in patients of type 2 diabetes mellitus, inadequately controlled with a stable dose of metformin or sulfonylurea or both.
- Trial name
- NCT01674348
- Testing
- P2202
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Piramal Enterprises Limited
Overweight, Obesity
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2.
- Trial name
- NCT06492135
- Testing
- survodutide
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Obese
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
- Trial name
- NCT07219589
- Testing
- HM17321
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy Volunteers
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects.
- Trial name
- NCT02475317
- Testing
- Maralixibat, Volixibat
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Overweight, Obesity
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks.
- Conditions
- Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression
- Trial name
- NCT07889570
- Testing
- Evolv GLP-1 Group, Control Group
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Evolv
Obesity, Overweight
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
evaluation of the EndoZip system procedure compared to the Apollo ESG procedure in obese patients.
- Trial name
- ESG (NCT07090005)
- Testing
- EndoZip System, OverStitch Endoscopic Suturing System (ESG)
- Where
- 5 sites in United States, Italy
- Volunteers
- 184 people
- Sponsor
- Nitinotes Surgical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.